|
Delayed
Japan Exchange
02:30:00 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 5,611.00 JPY | +0.94% |
|
+1.64% | +16.46% |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 8,876,382 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | -0.8% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 12,804,713 | 12,595,250 | 12,265,778 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 149.58% | -1.64% | -2.62% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 44.7x | 26.9x | 22.2x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.19x | 1.18x | 1.17x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 21.87x | 0.4x | 1.1x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 1.9x | 1.87x | 1.82x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 2.74x | 2.65x | 2.51x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 9.67x | 8.83x | 8.23x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 28.8x | 20.5x | 17.3x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 16.7x | 16.6x | 15.2x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 5.97% | 6.03% | 6.57% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.4 | 208.4 | 214.6 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 3.68% | 3.75% | 3.86% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 124.5 | 206.7 | 250.3 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 164% | 101% | 85.7% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,674,597 | 4,756,615 | 4,877,309 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,324,434 | 1,426,341 | 1,490,154 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 443,875 | 613,536 | 710,413 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 192,184 | 324,639 | 383,553 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,928,332 | 3,718,868 | 3,389,396 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 5,559.00 | 5,559.00 | 5,559.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,596,759 | - | - |
| Announcement Date | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/13/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 44.65x | 2.74x | 9.67x | 3.68% | 55.7B | |
| 34.32x | 12.47x | 25.45x | 0.57% | 1,078B | |
| 29.15x | - | - | 2.05% | 632B | |
| 32.02x | 7.45x | 15.48x | 2.73% | 443B | |
| 20.19x | 4.79x | 11.87x | 2.76% | 356B | |
| 21.62x | 5.6x | 13.97x | 2.87% | 289B | |
| 20.24x | 4.18x | 11.87x | 2.1% | 245B | |
| 26.43x | 6.88x | 12.21x | 2.41% | 226B | |
| 13.48x | 4.84x | 10.07x | 3.78% | 204B | |
| -42.9x | 6.13x | 34.58x | 2.39% | 171B | |
| Average | 19.92x | 6.12x | 16.13x | 2.53% | 369.94B | |
| Weighted average by Cap. | 24.83x | 8.09x | 18.49x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
